Pacific Biosciences of California Beheer
Beheer criteriumcontroles 2/4
De CEO Pacific Biosciences of California is Christian O. Henry, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.05M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 860.82K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 11.8 jaar.
Belangrijke informatie
Christian O. Henry
Algemeen directeur
US$8.0m
Totale compensatie
| Percentage CEO-salaris | 8.6% |
| Dienstverband CEO | 4.2yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 4yrs |
| Gemiddelde ambtstermijn bestuur | 11.8yrs |
Recente managementupdates
Recent updates
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Nov 12Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company
Nov 07
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely
Sep 20Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
Aug 21Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper
Jul 02We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas
Jun 03These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat
Apr 25It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$394m |
| Jun 30 2024 | n/a | n/a | -US$400m |
| Mar 31 2024 | n/a | n/a | -US$297m |
| Dec 31 2023 | US$8m | US$695k | -US$307m |
| Sep 30 2023 | n/a | n/a | -US$309m |
| Jun 30 2023 | n/a | n/a | -US$319m |
| Mar 31 2023 | n/a | n/a | -US$321m |
| Dec 31 2022 | US$7m | US$667k | -US$314m |
| Sep 30 2022 | n/a | n/a | -US$299m |
| Jun 30 2022 | n/a | n/a | -US$206m |
| Mar 31 2022 | n/a | n/a | -US$175m |
| Dec 31 2021 | US$3m | US$650k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$59m |
| Dec 31 2020 | US$13m | US$195k | US$29m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$51m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$100k | n/a | -US$84m |
| Sep 30 2019 | n/a | n/a | -US$115m |
| Jun 30 2019 | n/a | n/a | -US$111m |
| Mar 31 2019 | n/a | n/a | -US$109m |
| Dec 31 2018 | US$88k | n/a | -US$103m |
Compensatie versus markt: De totale vergoeding ($USD 8.05M ) Christian O. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.18M ).
Compensatie versus inkomsten: De vergoeding van Christian O. is gestegen terwijl het bedrijf verliesgevend is.
CEO
Christian O. Henry (56 yo)
4.2yrs
Tenure
US$8,046,575
Compensatie
Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.2yrs | US$8.05m | 0.14% $ 860.8k | |
| Chief Financial Officer | 4.2yrs | US$2.52m | 0.043% $ 262.0k | |
| Chief Operating Officer | 3.8yrs | US$4.60m | 0.12% $ 701.0k | |
| Chief Commercial Officer | 2.3yrs | US$2.53m | 0.050% $ 299.7k | |
| Co-Founder | 24.3yrs | US$466.76k | geen gegevens | |
| VP & Chief Accounting Officer | 3.5yrs | geen gegevens | 0.013% $ 80.3k | |
| General Counsel & Corporate Secretary | no data | geen gegevens | geen gegevens | |
| Chief People Officer | no data | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
49.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PACB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.3yrs | US$8.05m | 0.14% $ 860.8k | |
| Independent Director | 20.8yrs | US$259.00k | 0.0069% $ 41.7k | |
| Independent Director | 12.2yrs | US$255.00k | 0% $ 0 | |
| Independent Chairman | 11.3yrs | US$297.00k | 0.040% $ 243.7k | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 15.8yrs | US$265.00k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Chairman of Scientific Advisory Board | 2yrs | geen gegevens | geen gegevens |
11.8yrs
Gemiddelde duur
70yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PACB zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).